A large portfolio of great assets in the hands of inept management that can't execute. The company will be sold. While it remains in the hands of this group, the stock is in real trouble. It's absolutely irrelevant if ALS-2200 is superior to GS-7997; Gilead will be first to market and this team is losing Incivek share to Victrelis.
I'm sorry that's simply not true. It's certainly a tough hill to climb and there's certainly no guarantee of success but gen type 1 patients are included in their phase 3 trials. But really that's beside the point, what I'm try to convey even with a superior product the current Vertex team would not win the race. And anyone hoping this group will expedite these trials should take a long look at the continuing delays in the VX-661 trials.